Article
Oncology
Rong Li, Xing-Feng Pang, Zhi-Guang Huang, Li-Hua Yang, Zhi-Gang Peng, Jie Ma, Rong-Quan He
Summary: This study revealed that UBE2C mRNA and protein levels were highly expressed in ESCC and may play different roles in different stages of the disease. UBE2C mainly influences the biological function of esophageal cancer through synergistic effects with genes such as CDK1, PTTG1, and SKP2. Additionally, a potential UBE2C-related ceRNA network (HCP5/has-miR-139-5p/UBE2C) was constructed for ESCC.
Article
Biochemistry & Molecular Biology
Jingshi Liu, Yongdong Niu, Bin Zhang, Qisi Sun, Haiyi Li, Lu Bai, Zhongjing Su
Summary: The expression levels of GPER1 are found to be associated with tumor type and survival rates in esophageal carcinoma. In overall esophageal carcinoma, low expression of GPER1 is correlated with poor survival rates, while overexpression of GPER1 is associated with the development of esophageal adenocarcinoma and its pre-cancerous lesion. Furthermore, the protein expression of GPER1 is higher in esophageal adenocarcinoma tissues compared to normal esophageal tissues, whereas it is lower in esophageal squamous cell carcinoma tissues.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi
Summary: Esophageal cancer is a global public health concern with high mortality and disease burden. Esophageal squamous cell carcinoma, the predominant histological subtype, has unique etiology, molecular profiles, and clinicopathological features. Although systemic chemotherapy is the main therapeutic option, its clinical benefits are limited with poor prognosis. Personalized molecular-targeted therapies have not been successful in clinical trials. Therefore, there is an urgent need to develop effective therapeutic strategies for ESCC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Dentistry, Oral Surgery & Medicine
Su-Wen Zhu, Shuo Wang, Zhi-Zhong Wu, Qi-Chao Yang, De-Run Chen, Shu-Cheng Wan, Zhi-Jun Sun
Summary: This study revealed the overexpression of CD168 in oral squamous cell carcinoma (OSCC) tissues, which was associated with worse patient survival and pathological grade. Additionally, CD168 expression was positively correlated with other marker expression in OSCC.
Article
Genetics & Heredity
Shang-Wei Chen, Hua-Fu Zhou, Han-Jie Zhang, Rong-Quan He, Zhi-Guang Huang, Yi-Wu Dang, Xia Yang, Jun Liu, Zong-Wang Fu, Jun-Xian Mo, Zhong-Qing Tang, Chang-Bo Li, Rong Li, Li-Hua Yang, Jie Ma, Lin-Jie Yang, Gang Chen
Summary: Esophageal squamous cell carcinoma (ESCC) is the major histological type of esophageal cancers. The transcription factor PTTG1 was found to be highly expressed in ESCC tissues and may interact with target genes through chemokines and cytokine signaling pathways, particularly SLC25A17 and ERH. This suggests that PTTG1 may play a crucial role in the formation of ESCC by regulating downstream target genes.
FRONTIERS IN GENETICS
(2021)
Article
Medicine, General & Internal
Shu-Hui Lin, Chiao-Wen Lin, Jeng-Wei Lu, Wei-En Yang, Yueh-Min Lin, Hsueh-Ju Lu, Shun-Fa Yang
Summary: This study found that IGF2BP2 protein plays a clinicopathological role in OSCC patients and is associated with lymph node metastasis, cancer stage, and patient survival. Elevated cytoplasmic IGF2BP2 expression levels are correlated with poor overall survival in OSCC patients.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Cell Biology
Chorlada Paiboonrungruang, Emily Simpson, Zhaohui Xiong, Caizhi Huang, Jianying Li, Yahui Li, Xiaoxin Chen
Summary: Esophageal squamous cell carcinoma (ESCC) often exhibits mutated and hyperactive NRF2, leading to chemotherapy and radiotherapy resistance as well as poor survival rates. Therefore, there is a pressing need to develop NRF2 inhibitors for targeted therapy. Research focuses on NRF2 inhibitors and their mechanisms, screening novel drug targets, and evaluating NRF2 activity in the esophagus.
CELLULAR SIGNALLING
(2021)
Review
Pharmacology & Pharmacy
Xu Zhang, Yuxiang Wang, Linghua Meng
Summary: Esophageal cancer is a highly lethal disease with rapid progression and poor prognosis. The two major subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), have distinct risk factors and molecular characteristics. Although surgical and chemoradiotherapy approaches have been applied, molecularly targeted therapy for esophageal cancer is still in its early stages. Advances in large-scale next-generation sequencing have revealed genomic alterations in ESCC and EAC, providing insights into their roles in the development and progression of esophageal cancer. Potential therapeutic targets have been identified, and novel strategies are under development to combat this disease.
ACTA PHARMACEUTICA SINICA B
(2022)
Letter
Medicine, General & Internal
Muhammet Ozer, Ilyas Sahin, Hassan Abushukair, Aya Abushukair, Anwaar Saeed
Summary: The results of the CheckMate 648 trial demonstrate that nivolumab plus chemotherapy or nivolumab plus ipilimumab can prolong overall survival in patients with advanced esophageal squamous-cell carcinoma compared to chemotherapy alone. This survival benefit is significant among patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Li Liu, Ziyang Lu, Xiayun Hu, Tianyuan Su, Liping Su, Hongwei Pu
Summary: The study found that the proteins YAP1 and TAZ are highly expressed in esophageal squamous cell carcinoma (ESCC) and closely related to clinical and pathological parameters of the tumor. They may be involved in the development of ESCC and can be used as prognostic markers.
Article
Oncology
Liqing Qiu, Jing Yue, Lingyu Ding, Zihao Yin, Ke Zhang, Hongfang Zhang
Summary: In this review, the impact of cancer-associated fibroblasts (CAFs) on esophageal squamous cell carcinoma (ESCC) is highlighted, including the induction of chemoresistance, radioresistance, migration, invasion, and immune escape. The origin of CAFs and the influence of ESCC cells on CAF activation are also discussed. Furthermore, the clinical prospects and future trends of CAFs-targeted therapies in ESCC are emphasized. A better understanding of the molecular biology of CAFs may contribute to the development of novel anti-ESCC strategies.
Article
Oncology
Hidenari Hirata, Atsushi Niida, Nobuyuki Kakiuchi, Ryutaro Uchi, Keishi Sugimachi, Takaaki Masuda, Tomoko Saito, Shun-Ichiro Kageyama, Yushi Motomura, Shuhei Ito, Tadamasa Yoshitake, Daisuke Tsurumaru, Yusuke Nishimuta, Akira Yokoyama, Takanori Hasegawa, Kenichi Chiba, Yuichi Shiraishi, Junyan Du, Fumihito Miura, Masaru Morita, Yasushi Toh, Masakazu Hirakawa, Yoshiyuki Shioyama, Takashi Ito, Tetsuo Akimoto, Satoru Miyano, Tatsuhiro Shibata, Masaki Mori, Yutaka Suzuki, Seishi Ogawa, Kousei Ishigami, Koshi Mimori
Summary: A study sequencing 52 tumor samples from 33 ESCC patients who received radiotherapy combined with 5-fluorouracil/platinum revealed the impact of chemoradiotherapy on clonal evolution, with MYC gain potentially serving as a marker for therapy resistance. The findings enhance understanding of therapeutic resistance and support the rationale for precision chemoradiotherapy.
Article
Pathology
GaoMeng Luo, Yao Qi, ZhengYao Lei, XiaoYing Shen, MingMin Chen, LiLi Du, CaiXia Wu, JiaQi Bo, ShunLi Wang, Jun Zhao, XiangHua Yi
Summary: This study investigates the role of WTAP in esophageal squamous cell carcinoma (ESCC), finding that its expression is significantly upregulated in ESCC tissues and is correlated with lymph node metastasis, TNM stage, and overall survival. Knocking down WTAP inhibits cell proliferation and migration while promoting apoptosis, suggesting its involvement in ESCC-genesis.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Chemistry, Multidisciplinary
Yongxu Jia, Baifeng Zhang, Chunyang Zhang, Dora Lai-Wan Kwong, Zhiwei Chang, Shanshan Li, Zehua Wang, Huiqiong Han, Jing Li, Yali Zhong, Xin Sui, Li Fu, Xinyuan Guan, Yanru Qin
Summary: In this study, the authors analyzed the transcriptomes of 85,263 single cells from four ESCC patients with lymph node metastasis. They identified various cells and genes that play a role in the metastatic microenvironment, including IFIT3(+) T and B cells, APOC1(+)APOE(+) macrophages, myofibroblasts, and immunoglobulin genes. They also discovered an epithelial-immune dual expression program that regulates immune processes in metastatic cells. Additionally, they found differential intercellular communications in the metastatic ESCC microenvironment, mainly involving the interaction of APOC1(+)APOE(+) macrophages with tumor and stromal cells. These findings provide insights into the molecular mechanisms underlying lymph-node metastasis and offer potential targets for inhibiting tumor growth and improving clinical outcomes.
Article
Oncology
Guo-Sheng Li, Lin-Jie Yang, Gang Chen, Su-Ning Huang, Ye-Ying Fang, Wei-Jian Huang, Wei Lu, Juan He, He-Chuan Liu, Lin-Yi Li, Bin-Yu Mo, Hui-Ping Lu
Summary: The study found that high expression of CDC45 in laryngeal squamous cell carcinoma (LSCC) may demonstrate carcinogenic effects, making it a potential target for screening and treating LSCC.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2022)